The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.

M Haluzík; G Fulcher; Thomas Pieber; L Bardtrum; D Tutkunkardas; HW Rodbard

doi:10.1111/dom.13261

The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.

M Haluzík
, G Fulcher
, Thomas Pieber
, L Bardtrum
, D Tutkunkardas
, HW Rodbard

Division of Endocrinology and Diabetology

Research output: Contribution to journal › Research article

16 Citations (Web of Science)

Original language	English
Journal	Diabetes, Obesity and Metabolism
DOIs	https://doi.org/10.1111/dom.13261
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Branches of science

301 Medical-Theoretical Sciences, Pharmacy
302 Clinical Medicine
305 Other Human Medicine, Health Sciences

Research Fields

Sustainable Health Research

DOI

10.1111/dom.13261

Links

Cite this

Haluzík, M., Fulcher, G., Pieber, T., Bardtrum, L., Tutkunkardas, D., & Rodbard, HW. (2018). The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13261

Haluzík, M ; Fulcher, G ; Pieber, Thomas et al. / The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. In: Diabetes, Obesity and Metabolism. 2018.

@article{2c4f1e4d32cf498eb373ce4dfa755422,

title = "The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.",

author = "M Haluz{\'i}k and G Fulcher and Thomas Pieber and L Bardtrum and D Tutkunkardas and HW Rodbard",

year = "2018",

doi = "10.1111/dom.13261",

language = "English",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "John Wiley and Sons Inc",

}

Haluzík, M, Fulcher, G, Pieber, T, Bardtrum, L, Tutkunkardas, D & Rodbard, HW 2018, 'The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.', Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13261

The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. / Haluzík, M; Fulcher, G; Pieber, Thomas et al.
In: Diabetes, Obesity and Metabolism, 2018.

Research output: Contribution to journal › Research article

TY - JOUR

T1 - The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.

AU - Haluzík, M

AU - Fulcher, G

AU - Pieber, Thomas

AU - Bardtrum, L

AU - Tutkunkardas, D

AU - Rodbard, HW

PY - 2018

Y1 - 2018

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000435082500004

UR - https://pubmed.ncbi.nlm.nih.gov/29451706

UR - https://pmc.ncbi.nlm.nih.gov/articles/PMC6033009

U2 - 10.1111/dom.13261

DO - 10.1111/dom.13261

M3 - Research article

C2 - 29451706

SN - 1462-8902

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

ER -

Haluzík M, Fulcher G, Pieber T, Bardtrum L, Tutkunkardas D, Rodbard HW. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2018. doi: 10.1111/dom.13261